Mavatar is a global leader in AI-powered precision medicine, built on more than 20 years of scientific innovation. While most life science AI projects start with generic models and try to adapt them to biology, Mavatar has done the opposite- designing its AI from the ground up for biomedical decision-making.
At the core is DINA (Deep Integrated Network Analysis)—a proprietary vertical AI and data-driven framework trained on harmonized transcriptomic data across tissues, diseases, and populations. Unlike generative models or general-purpose tools, DINA is engineered specifically for reasoning within complex biological systems: understanding what happens, why it happens, and what happens if we intervene.
This intelligence powers two commercial platforms;
- Mavatar Discovery – supporting the acceleration of drug discovery, repurposing, and trial design for pharma and researchers.
- Mavatar Precision – delivering real-time, personalized treatment guidance to clinicians based on patient-specific molecular
profiles.
By simulating digital twins of both patients and diseases, Mavatar enables predictive matching between disease mechanisms and therapies.
As medicine shifts from one-size-fits-all to highly personalized care, Mavatar is uniquely positioned to lead this transformation and capture value across a multibillion-dollar global market.
